CSIMarket


Immuneering Corporation  (IMRX)
Other Ticker:  
 


 

Immuneering Corporation

IMRX's Financial Statements and Analysis



Immuneering Corporation increased forth quarter of 2023 net loss per share of $-0.47 compare to net loss per share of $-0.38 recorded in the same quarter a year ago a decrease compare to $-0.43 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.47 $  0 Mill
$-0.09     Unch.    



Immuneering's Revenue fell by 0 % in forth quarter of 2023 (Dec 31 2023) year on year, to $0 million and declined by sequentially.


Immuneering is

More on IMRX's Income Statement



Immuneering's in theforth quarter of 2023 recorded net loss of $-15.083 million, an increase from net loss of $-13.246 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on IMRX's Growth

Immuneering Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-9 million

More on IMRX's Cash flow Statement


Immuneering Corporation does not pay out common stock dividend.

In trailing twelve-month period Immuneering Corporation payed $ -1.72 cash per share, on a free-cash flow basis .

Book value fell by -10.40 % sequentially to $3.18 per share, -20.10% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.94 per share from $ 3.31.

Company repurchased 0.82 million shares or 2.82 % in Dec 31 2023.


More on IMRX's Dividends

 Market Capitalization (Millions) 68
 Shares Outstanding (Millions) 28
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 11




Immuneering Corporation does not pay out common stock dividend.

In trailing twelve-month period Immuneering Corporation had negative $ -1.72 cash flow per share, on a free-cash flow basis .

Book value fell by -10.40 % sequentially to $3.18 per share, -20.10% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 2.94 per share from $ 3.31.

Company repurchased 0.82 million shares or 2.82 % in Dec 31 2023.


More on IMRX's Balance Sheets

 Market Capitalization (Millions) 68
 Shares Outstanding (Millions) 28
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 11
   


  News about Immuneering Corporation Earnings

Financial Struggles Cast Shadow on Immuneering Corporation's Promising Drug Development Milestone



Immuneering Corporation (Nasdaq: IMRX) has recently garnered attention for being granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for their lead asset IMM-1-104 in the treatment of pancreatic ductal adenocarcinoma (PDAC). While this development has generated excitement within the medical community, a closer look at the company's financials raises concerns about its long-term sustainability. Immuneering Corporation's weak performance in recent quarters, coupled with stagnant revenue growth, cast doubts on its ability to capitalize on the potential offered by IMM-1-104. In this article, we analyze the company's financials and explain why investors should be cautious about...

Immuneering Corporation's Financial Results and Potential Impact on Future Operations and Revenue Growth



Immuneering Corporation, a renowned biotechnology company trading on the NASDAQ, has experienced a decline in stock value over the past five trading days. Despite this setback, the company's year-to-date performance remains commendable. Notably, Immuneering Corporation's financial results reveal noteworthy developments in their benchmarking efforts and revenue stability. As we explore these facts, it is essential to consider how they might impact the company's future operations and prospects.
1. Promising Benchmarking Results:
Immuneering Corporation recently conducted an expanded benchmarking study using its product, IMM-1-104, as a single agent across over 190 patient-aligned models in hu...

Immuneering Corporation Reports Promising Second Quarter 2023 Performance, Reveals Improved Profitability and Steady Financial Trajectory!



The recently released financial results for Immuneering Corporation's fiscal period ending June 30, 2023, have provided insights into the company's performance and direction. By examining various critical indicators such as per share loss, EPS improvement, revenue stability, and net shortfall, we can speculate on the possible impacts they may have on the company's future prospects.
Positive Shift in Per Share Loss and EPS:
In a positive development, Immuneering Corporation managed to decrease its per share loss from $-0.44 to $-0.43 compared to the previous year. Although seemingly small, this reduction indicates a gradual improvement in the company's ability to control its expenses. Furthe...

Headline: Immuneering Corporation's Diminishing Returns Intensify Further in January-March 2023

Investors in Immuneering Corporation may want to exercise caution, as the company continues to record disappointing financial figures. As of 12 months ending in the first quarter of 2023, Immuneering Corporation has recorded a cumulative net loss of $-51 million. This has resulted in a negative return on equity (ROE) of -44.24%, which is significantly lower than many other companies within the Major Pharmaceutical Preparations industry.
As of the current quarter, Immuneering Corporation ranks at 1417 in terms of overall ROE ranking. This is an improvement from the fourth quarter of 2022, where the company was ranked at 3326. Howeve...


Date modified: 2024-03-06T16:49:52+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com